Are Peptides Legal Now? What HHS’s 2026 Compounding Policy Actually Allows
Quick answer: As of October 28 2026, the Department of Health and Human Services (HHS) released a policy that lets compounding pharmacies make six specific peptides without the FDA stepping in, as long as strict conditions are met. The six are BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax. The peptides are still not FDA-approved, and […]
By Astra Editorial Team
Medically reviewed by Dr. Michael Wasef, Medical Director, Wasef Health · Board-Certified Internal Medicine
Published:
Updated:
Quick answer: As of October 28 2026, the Department of Health and Human Services (HHS) released a policy that lets compounding pharmacies make six specific peptides without the FDA stepping in, as long as strict conditions are met. The six are BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax.
The peptides are still not FDA-approved, and this is a temporary enforcement policy, not legalization. You would still need a prescription and a licensed compounding pharmacy to obtain them.
Key takeaways
- HHS will not take action against pharmacies that compound six peptides: BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax.
- This is “enforcement discretion,” not approval. The peptides are still not FDA-approved.
- Each peptide is covered only for certain uses, such as injection, pill, or nasal spray. Other uses are not protected.
- Pharmacies must follow strict rules on sourcing, testing, labeling, and safety reporting.
- The policy is temporary. HHS can cancel it if safety problems appear.
- To get these peptides legally, you will need a prescription and a licensed compounding pharmacy.
What does “enforcement discretion” mean?
Quick answer: It means the FDA is choosing not to punish pharmacies that compound these six peptides, even though the peptides are not approved. The law did not change. The FDA just agreed to look the other way for now, as long as pharmacies follow the rules.
Compounded drugs are not FDA-approved. The FDA does not check their safety, quality, or how well they work before they reach a patient. Federal law only lets a pharmacy compound with a raw drug ingredient in a few situations. One of them is when that ingredient sits on an approved list called the 503A bulks list, which currently does not include any of the six peptides (BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax).
Enforcement discretion is the workaround for this. In practice, the FDA is still writing the rules that will decide which peptides make the official list. While it finishes that work, HHS says it will not take action against licensed pharmacies, federal facilities, or doctors who compound these six, as long as they follow a set of conditions.
HHS also made clear it can pull the policy back, fully or in part, if a safety or quality problem shows up. This is a temporary pause with strings attached, not a permanent decision.
What peptides are legal to compound in 2026?
Quick answer: Six peptides are covered: BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax. Each one is allowed only for certain uses, such as an injection, a pill, or a nasal spray.
The policy does not treat the six the same way. It links each peptide to the specific uses the evidence supports. Anything outside those uses is not protected. A pharmacy making Semax as an injection, for example, would fall completely outside the policy.
| Peptide | What it’s used for | Allowed uses |
|---|---|---|
| BPC-157 | Healing and recovery (lab-made peptide) | Injection (under the skin or into muscle), a pill, or on the skin |
| TB-500 | Recovery | Injection under the skin or into muscle only |
| Epitalon | Anti-aging | Injection, and only in short on-and-off courses (not continuous) |
| MOTS-c | Metabolism (tied to the cell’s energy system) | Injection |
| Semax | Focus or brain aid | Nasal spray only |
| KPV | Fights inflammation | On the skin or as a pill |
Why did HHS allow peptide compounding?
Quick answer: The FDA’s own drug reviewers said no to all six peptides. An outside expert panel said yes. HHS went with the panel, which is unusual, and it did so while the science is still thin.
Inside the FDA, the Center for Drug Evaluation and Research, the staff who actually review drugs, recommended against listing all six peptides. The outside expert panel, called the Pharmacy Compounding Advisory Committee, voted the other way in July. HHS went with the panel instead of its own reviewers.
HHS gave two main reasons. The first is about reducing harm. A big gray market for these peptides already exists, fed by “research-use-only” powders from overseas sellers with no quality checks. HHS argues that a regulated pharmacy is a safer option.
The second reason is about evidence. HHS says the testing has improved since the FDA’s first review, because labs now provide batch-by-batch results that confirm what is in each product and that it is clean.
Peptides have also become popular within the “Make America Healthy Again” movement, and this policy is a clear win for that group. Critics in mainstream medicine argue that for most of these peptides, strong human evidence on safety and benefit is still missing, and pausing enforcement does not create that evidence.
Peptide compounding timeline: How we got here
Quick answer: These peptides spent more than two years flagged by the FDA before HHS cleared a path to compound them in October 2026.
- Sept 2023. The FDA places BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax in “Category 2,” flagging safety concerns and keeping them out of compounding.
- April 2026. The FDA removes them from Category 2, but they still cannot be legally compounded.
- July 2026. An FDA advisory panel votes to recommend the six peptides and rejects a seventh, which is emideltide.
- Oct 28, 2026. HHS issues its enforcement-discretion policy, allowing the six to be compounded under strict conditions.
What are the rules for compounding these peptides?
Quick answer: Pharmacies must use one peptide per product, buy from FDA-registered suppliers with lab test results, require a real prescription, report safety problems, and label products honestly. Strict testing is required as well.
The policy comes with 10 conditions, the most important of which are as follows:
- One peptide per product. Each product can hold only a single peptide from the list. No stacks, no blends. This makes it easier to trace any side effect back to a specific peptide.
- Checked source material. The raw peptide has to come from an FDA-registered maker and arrive with a lab report. The report must show it was tested for identity, strength, and contaminants like bacterial toxins, heavy metals, and germs.
- A real prescription. Each product needs a prescription written for a specific patient. This is still compounding, not an over-the-counter product.
- Safety reporting. Pharmacies must report serious problems to the FDA’s MedWatch system, so regulators can catch issues early.
- Honest labels and a cleared needle. Products must be labeled as compounded and not for resale, and the only device allowed is an FDA-cleared syringe.
The testing bar behind these rules is high. The guidance calls for several lab methods, strict limits on impurities, and checks for bacteria and toxins, among others.
What this means if you want to try peptides
Quick answer: For the first time, there is a clear, legal way to get these six peptides through a licensed prescriber and pharmacy. But they are still not FDA-approved, and the policy could be pulled at any time.
For patients and the telehealth companies that serve them, the policy creates a legal, above-board way to get these six peptides through a licensed pharmacy and a prescriber, instead of a sketchy overseas seller. For pharmacies willing to meet the testing and reporting rules, it removes much of the legal risk that kept them away.
What’s next for peptide regulation?
Quick answer: The FDA still has to write formal rules that decide which peptides make the permanent list. Until then, these six are legal to compound only under tight limits, and the rules could still change.
This policy buys time while the FDA decides, through official rules, which peptides earn a permanent spot on the 503A list and which do not. One peptide that went before the same panel in July, emideltide, was turned down, showing that the door is not open to everything.
Until the rules are final, these six peptides remain not FDA-approved yet not quite banned and legal to compound only inside tight limits.
Where can I get compounded peptides legally?
Quick answer: Through a licensed prescriber and a compounding pharmacy that follows the policy’s rules. You cannot buy these over the counter.
You can get these six peptides legally through a licensed prescriber and a compounding pharmacy that meets the policy’s testing, sourcing, and reporting conditions. Telehealth platforms such as Astra (try-astra.com) connect patients with licensed clinicians who can evaluate whether a peptide is appropriate and coordinate compounding through a licensed pharmacy.
The policy created a legal path. Walk it with a provider that actually fits the rules.
Astra connects you with licensed clinicians who coordinate compounded peptides through compliant pharmacies. No research-grade shortcuts, no vague sourcing.
See Astra’s peptide lineup Takes about 5 minutes to start.📖 What to Read Next
Frequently Asked Questions
Six specific peptides (BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax) can now be compounded under a temporary HHS enforcement-discretion policy, as long as pharmacies meet strict conditions. The peptides remain non-FDA-approved, the policy is interim, and HHS can withdraw it if safety problems emerge. Peptides outside the list of six are not covered.
A compounded drug is a medication that a licensed pharmacist mixes or prepares to fit a specific patient’s needs. Compounded drugs are not FDA-approved, so the FDA does not review their safety, quality, or effectiveness before they reach patients. Compounding is legal and common, but it follows different rules than mass-produced, FDA-approved medicines.
BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax. Each is limited to specific routes of administration, so an allowed peptide made in a route the policy does not cover falls outside the protection.
No. The FDA’s own drug-review center actually recommended against listing all six; an outside advisory panel disagreed, and HHS went with the panel on an interim basis.
BPC-157 is one of the six peptides covered, and the policy allows it to be compounded for injection, oral, or topical use. But it still requires a patient-specific prescription and a licensed compounding pharmacy. Buying “research-use-only” BPC-157 from an unregulated online seller is a different thing and is exactly the gray market the policy is trying to pull people away from.
No. It is an interim measure that holds only until the FDA completes formal rulemaking on which peptides belong on the official 503A list. HHS can revise or revoke it at any point, particularly if a safety or product-quality signal appears.
Related Astra programs
This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.